The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
Open accessPublished version of a preprint
Abstract
Abstract Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclinical models of HER2-positive breast cancer and in 24 patients with primary HER2-positive breast cancer undergoing trastuzumab-containing neoadjuvant treatment. In mice, the antitumor activity of trastuzumab was impaired by antibiotic administration or fecal microbiota transplantation from antibiotic-treated donors. Modulation of the intestinal microbiota was reflected in tumors by impaired recruitment of CD4+ T cells and granzyme B–positive cells after trastuzumab treatment. Antibiotics caused reductions in dendritic cell (DC) activation and the release of IL12p70 upon trastuzumab treatment, a mechanism that was necessary for trastuzumab effectiveness in our model. In patients, lower α-diversity and lower abundance of Lachnospiraceae, Turicibacteraceae, Bifidobacteriaceae, and Prevotellaceae characterized nonresponsive patients (NR) compared with those who achieved pathologic complete response (R), similar to antibiotic-treated mice. The transfer of fecal microbiota from R and NR into mice bearing HER2-positive breast cancer recapitulated the response to trastuzumab observed in patients. Fecal microbiota β-diversity segregated patients according to response and positively correlated with immune signature related to interferon (IFN) and NO2-IL12 as well as activated CD4+ T cells and activated DCs in tumors. Overall, our data reveal the direct involvement of the gut microbiota in trastuzumab efficacy, suggesting that manipulation of the gut microbiota is an optimal future strategy to achieve a therapeutic effect or to exploit its potential as a biomarker for treatment response. Significance: Evidence of gut microbiota involvement in trastuzumab efficacy represents the foundation for new therapeutic strategies aimed at manipulating commensal bacteria to improve response in trastuzumab-resistant patients. See related commentary by Sharma, p. 1937
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In breast cancer, high baseline gut microbiota alpha diversity has been associated with response to both neoadjuvant HER2 blockade and neoadjuvant chemotherapy [8, 12].”
From Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer (2025) · cites this paper as [12]
In the citing paper
“Additionally, families like Lachnospiraceae, Turicibacteraceae, and Prevotellaceae are more abundant in breast cancer patients achieving pathologic complete responses to trastuzumab-containing regimens (Di Modica et al., 2021).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Di Modica et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“This intervention has also been under investigation for immune checkpoint inhibitor agents (49) based on a similar reduction in bacteria associated with fiber consumption found in NR patients (15).”
BackgroundRecognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Cited by
Sorted by citations
Items 101–188 of 188
Xu, Y., Chang, S., Qian, J., Yu, X., Wang, S., Shao, L., & Yu, W. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03710-2 · Cited by 5
Unwanted passengers: Microbes hitchiking in breast cancer metastases
Parida, S., & Drewes, J. L. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.05.010 · Cited by 5
Firmicutes in gut microbiota: hormonal influence on breast cancer in obese individuals
Chen, J., Zhang, Z., Ma, M., Huang, Q., Ling, Z., Liu, Y., Gao, Z., Wang, S., Zhu, Y., Zhang, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03562-4 · Cited by 4
The role of gut microbiota in breast cancer: biomarker identification and therapeutic applications
Abrishami, M., Sabouri, M., Joneidi, F., Haghshenas, Z., Khalili‐Tanha, G., & Nazari, E. (2025) · Antonie van Leeuwenhoek · doi:10.1007/s10482-025-02217-2 · Cited by 4
The role of the microbiota in cancer drug resistance and emerging therapeutic strategies
Che, C., Zhou, Y., Chen, L., Li, S., fan, D., Lu, Y., & Zhao, X. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218305 · Cited by 4
Chong, N., Yao, L., Wang, M., & Xu, Y. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00219-8 · Cited by 4
Lin, Z., Mu, S., Zhang, W., Guo, Y., Dong, C., Song, L., Zhang, H., Wu, R., Luo, P., & Liang, L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102428 · Cited by 4
Barbosa, E. C., Bucar, E. E. C., JUBÉ, G. R., SILVEIRA, L. B., SILVA, N. C. D., FARIA, P. C. C., Ramos, P., Moraes, V. R. Y., & BARROS, J. O. B. (2023) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20233490-en · Cited by 5
Qin, Y., Su, S., Dai, G., & He, L. C. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230707112244 · Cited by 4
Xiong, Y., Zhang, X., Niu, X., Zhang, L., Jia, J., & Xu, A. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1417904 · Cited by 5
Zhou, Y., Jiang, M., Li, X., Shen, K., Zong, H., Lv, Q., & Shen, B. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1490007 · Cited by 4
Endoscopic surgery affects the gut microbiota and its metabolism in breast cancer patients
Li, J., Gao, F., Li, R., Chen, Z., Chen, G., Fan, P., & Du, G. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1481582 · Cited by 4
Towards Taming the Bugs to Improve the Drugs for Breast Cancer
Sharma, D. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0300 · Cited by 4
Vilhais, G., Costa, D. A., Fontes-Sousa, M., Ribeiro, P. C., Martinho, F., de Sousa, C. B., dos Santos, C. R., Negreiros, I., Canastra, A., Borralho, P., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1360737 · Cited by 5
Zhao, B., Zhou, B., Li, Q., Su, C., Ma, J., & Yang, L. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.70006 · Cited by 3
Wu, Q., Zhou, Y.-R., Chen, Z.-R., Liu, M.-X., Liu, M.-X., Liu, Y.-F., Li, Z., Zhao, Q.-R., Zhang, Y.-Q., Zhang, H., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105230 · Cited by 4
Host–microbiome interactions in breast cancer progression and treatment response
Bautista, J., Lara-Hernández, M. E., Cruz, M. H.-D. L., Andino-Araque, V., León-Rivera, M., & López‐Cortés, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1827694 · Cited by 4
Advances and challenges in microbiome transplantation
Sen, P., Kaulmann, D., Youngster, I., Abdeen, S. K., & Elinav, E. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.06.006 · Cited by 4
Guo, Z., Xu, C., Fang, Z., Yu, X., Yang, K. G., Liu, C., Ning, X., Dong, Z., & Liu, C. (2024) · Medicine · doi:10.1097/md.0000000000038392 · Cited by 3
Wu, D., Thompson, L. U., & Comelli, E. M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02290-23 · Cited by 3
Zhang, Z., & Sang, L.-X. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i36.4025 · Cited by 4
Kim, N., Kim, J., Choi, J. H., & Kim, R. (2025) · Biomaterials Science · doi:10.1039/d5bm00612k · Cited by 2
Focus on gut microbes: new direction in cancer treatment
Liao, L., Zeng, M., Liu, D., He, Y., Du, W., & Cao, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1505656 · Cited by 3
The microbiome shaping cancer development, progression, and therapeutic response
Salihoğlu, R. (2025) · Physiological Genomics · doi:10.1152/physiolgenomics.00091.2025 · Cited by 3
The human microbiome reshapes the breast cancer immune-metabolic-hormonal microenvironment
Wang, Q., 张富荣, Xin, Y., Yang, R., Tang, Z., Wu, Z., & Ming, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1774211 · Cited by 2
Su, X., Li, A., Liu, J., Guo, Y., Yu, H., Yu, J., Wang, R., Garza, D. R., Qu, J., Wen, B., et al. (2026) · Microbiological Research · doi:10.1016/j.micres.2026.128539 · Cited by 3
Li, L., Yang, C., Wang, Z., Zhou, B., Zhang, Y., Liu, H. B., Sun, S., Chen, M., Hu, X., Jia, F., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.011 · Cited by 2
Martinelli, S., Lamminpää, I., & Amedei, A. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-888 · Cited by 2
Jia, Z., Liu, X., & Liao, W. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03948-23 · Cited by 2
Deng, X., Yang, H., Tian, L., Ling, J., Ruan, H., Ge, A., Liu, L., & Fan, H. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1393422 · Cited by 3
Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review
Guardamagna, M., Meyer, M., Berciano‐Guerrero, M., Mesas-Ruiz, A., Cobo, M., Pérez-Ruiz, E., Cantero, A., Lavado-Valenzuela, R., Barragán, I., Oliver, J., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-216 · Cited by 2
Wang, X., Gao, H., Zeng, Y., & Chen, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1450298 · Cited by 3
Gut microbiota - A key player in breast cancer initiation and progression: A narrative review
Mohamed, N., Madyan, E. F., Yasser, A., Attia, M. G., Abdel-Ghany, S. E., & Sabit, H. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_325_23 · Cited by 2
Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment
Dari, M. A. G., Ghaedrahmati, F., Moalemnia, A., Dezfouli, M. A., Savari, F., Zamani, A. M., Ahmadi, B., Nazarbeigi, M., Farzaneh, M., & Zehtabi, M. (2025) · Current Molecular Medicine · doi:10.2174/0115665240351595250213103451 · Cited by 2
Liu, X., Yang, S., & Liu, L. (2025) · BMC Cancer · doi:10.1186/s12885-025-14281-y · Cited by 2
McDonnell, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062040 · Cited by 1
Ullern, A., Holm, K., Andresen, N. K., Røssevold, A. H., Bang, C., Naume, B., Hov, J. R., & Kyte, J. A. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70117 · Cited by 3
Gut Microbiota: An Innovative Traditional Chinese Medicine Perspective on Breast Cancer Therapy
Ding, H., Chen, Y., Yu, Q., Li, H., & Gao, X. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096400579250924110355 · Cited by 1
Rao, Y., Wang, S., Liu, X., Shao, C., & Li, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03838-9 · Cited by 1
Oh, B., Lamoury, G., Carroll, S., Morgia, M., Boyle, F. M., Pavlakis, N., Clarke, S., Guminski, A. D., Menzies, A., Diakos, C., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1666830 · Cited by 1
Mamun, M. A. A., Rakib, A., Mandal, M., Li, W., Miller, D. D., Chen, H., Nagarkatti, M., Nagarkatti, P. S., & Singh, U. P. (2026) · Cells · doi:10.3390/cells15020141 · Cited by 1
Microbiota as a modulator of drug response: targeting microbial–drug crosstalk in cancer therapy
Zhao, T., Liu, M., Qiu, L. X., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Luo, P., Huang, J., & Cheng, Q. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2651930 · Cited by 1
The dialogue between breast cancer and microorganisms
Zeng, Y., Jiang, Y., Huang, Y., Yin, S., Yang, Z., & Zhang, F. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1738739 · Cited by 1
He, J.-J., Hu, C.-J., & Yang, S. (2023) · PubMed Central · doi:10.12182/20230560107 · Cited by 1
Barbosa, E. C., Bucar, E. E. C., JUBÉ, G. R., SILVEIRA, L. B., SILVA, N. C. D., FARIA, P. C. C., Ramos, P., Moraes, V. R. Y., & BARROS, J. O. B. (2023) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-6991e-20233490 · Cited by 1
Wu, C.-Y., Huang, C., Hong, W., Liu, Y. C., Shih, M.-C., & Lin, J.-C. (2023) · Metabolites · doi:10.3390/metabo13090999 · Cited by 1
Carbohydrate quality vs quantity on cancer Risk: Perspective of microbiome mechanisms
Liu, L., Sun, T., Liu, H., Li, J. J., & Li, T. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106246 · Cited by 3
The Microbiome: A New Frontier in Overcoming Drug Resistance in Breast Cancer
Luvhengo, T. E., Miya, T. V., Basera, A., Fadebi, O. O., Mehrotra, R., & Dlamini, Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-52860-6_11 · Cited by 1
Ho, M. P., & Bonavida, B. (2025) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2025058633 · Cited by 1
Microbiome and breast cancer: A systematic review and meta-analysisPreprint
Thu, M. S., Chotirosniramit, K., Nopsopon, T., Hirankarn, N., & Pongpirul, K. (2022) · medRxiv · doi:10.1101/2022.12.30.22284053 · Cited by 1
EFEITOS DO USO DE PROBIÓTICOS NO TRATAMENTO DO CÂNCER COLORRETAL
Rizzo, E. P. M., Bernardes, G. R. M., de Campos, M. C. A. V., Fagundes, S. M., Moraes, V. R. Y., & Carrijo, J. B. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-5
A MICROBIOTA COMO ALTERNATIVA DIAGNÓSTICA E TERAPÊUTICA PARA O CÂNCER DE MAMA
Borges, G. H. D. O. C., Diniz, L. D. P., Silva, L. M. P., Pinto, R. E. S., Filho, C. G. C., & de Oliveira, D. A. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-2
SÍNDROME DE RUBINSTEIN-TAYBI E SEU EFEITO NA PSIQUE
de Souza, I. L. G., Rangel, T. D. S., de Oliveira, A. C. G., Pereira, V. R. D., Lima, L. L. M., & Vidal, O. I. D. S. R. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-9
de Souza, A. L. B., Vasconcellos, J. R. S., Saraiva, Y. D. O., Fagundes, S. M., Bernardes, G. R. M., & Carneiro, W. M. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-3
PRINCIPAIS IMPACTOS PSICOSSOCIAIS DA CIRURGIA PLÁSTICA PEDIÁTRICA RECONSTRUTIVA
Soares, R. A., Perini, R. L. M., Bernardes, R. R., Monteiro, V. H. C., & Freitas, A. D. A. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-8
Déroulède, L. F., de Campos, A. P. M., Ferreira, I. R., Maia, J. J., & Almeida, D. S. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-4
Machado, F. M., Castro, B. V., de Arruda, G. A. V., Silva, G. D. O. A., Leite, K. N., & de Oliveira, D. A. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-10
IMUNOTERAPIA NO CÂNCER DE MAMA TRIPLO-NEGATIVO
dos Santos, M. E. I., Pereira, A. P. M., Barros, G. F. A., Fagundes, S. M., Rangel, T. D. S., & Carrijo, J. B. (2023) · Amplla Editora eBooks · doi:10.51859/amplla.ctc976.1123-6
Intestinal Microbiota in the Clinical Results of Cancer and Its Modulation as Auxiliary Therapy
Claudino, L. R. F., & Ferreira, S. B. (2023) · doi:10.3390/ecm2023-16583
Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
张, 立. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143712
Hong, W., Huang, G., Wang, D., Xu, Y., Qiu, J., Pei, B., Qian, D., & Meng, X. (2023) · Figshare · doi:10.6084/m9.figshare.24054367
Hong, W., Huang, G., Wang, D., Xu, Y., Qiu, J., Pei, B., Qian, D., & Meng, X. (2023) · Figshare · doi:10.6084/m9.figshare.24054361
Hong, W., Huang, G., Wang, D., Xu, Y., Qiu, J., Pei, B., Qian, D., & Meng, X. (2023) · Figshare · doi:10.6084/m9.figshare.24054364
Hong, W., Huang, G., Wang, D., Xu, Y., Qiu, J., Pei, B., Qian, D., & Meng, X. (2023) · Figshare · doi:10.6084/m9.figshare.24054355
Intestinal Microbiota as a Determinant of Effectiveness and Safety of Anticancer Therapy
Karłowicz-Bodalska, K., Bęben, D., Janicka, N., Gądek, Ł., & Bodalska, G. (2024) · Farmacja Polska · doi:10.32383/farmpol/190217
Carson, T. L., Rivers, D. A., Doerr, V., Haver, M. K., & Byrd, D. A. (2024) · Current Epidemiology Reports · doi:10.1007/s40471-024-00351-5
Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance
McWhorter, R., Libra, M., & Bonavida, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00014-2
Li, H., Li, H., Liu, Y., Chen, C., Liu, X., & Li, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4667151/v1
Predictors of Immunotherapy Response in Triple Negative Breast Cancer
Hu, Y., Yoder, R., & Sharma, P. (2025) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00575-4
Gut Microbiota, Breast Cancer, and Neoadjuvant Therapy
夏, 晨. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153606
Research Advances in the Association between Gut Microbiota and HER2-Positive Breast Cancer
龙, 腾. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1561834
Dietary index for gut microbiota, genetic risk, and incidence of breast cancer: a prospective study
Chen, X., Wang, Y., Li, D.-R., Liu, B.-Q., Fang, Q., Chen, Y.-H., Liu, J., Ni, C., Zheng, W.-R., Liu, J., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02093-8 · Cited by 1
Guo, L., Zhou, C., Xi, W., Yang, L., Chang, Q., Qu, Q., Jiang, J., Wu, J., Cai, Q., Yan, J., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2595908
Ruocco, G. (2026) · International Journal of Heat and Mass Transfer · doi:10.1016/j.ijheatmasstransfer.2026.128606
Luo, N., Li, X., Hu, Y., Guo, L., & Zhang, K. (2026) · Phytotherapy Research · doi:10.1002/ptr.70278
Liang, H., Sun, X., Shi, G., Chen, H., & Li, J. (2026) · Medicine · doi:10.1097/md.0000000000048411
Precision nutrition in breast cancer: Towards patient- and tumour-informed dietary strategies
Crespo-Garcia, C., Taaffe, D. R., Peddle‐McIntyre, C. J., Jeffery, E., Campbell, J. P., Thomas, R., Galvao, D. A., & Newton, R. U. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106670
Zalabardo-Aguilar, M., Fernandez, I., Girona, A., González, A., Blanco, J., Campos, O., Sánchez‐Muñoz, A., Onieva, J. L., Jerez, J. M., Pascual, J., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104833
The role of human microbiota in breast cancer pathogenesis and treatment
Qiu, J., Wang, X., Li, M. M., Guo, J., Ning, S., Gao, Y., Zhang, X., Meng, X., Chen, Y., & Zhou, Y. (2026) · iMeta · doi:10.1002/imt2.70142
The role of microbiome–mucosal barrier interactions in neoplastic diseases
Toth, E., Sipos, A., Mikó, E., Nyerges, P., & Bai, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00007-7
Diet and breast cancer: New perspectives on nutrition, metabolism, and immunity
Li, R., Jiang, X., Lu, Y., Zhou, S., Chen, M., Yu, S., Wu, J., Jia, X., Xie, D., & Zhong, X. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156717
Alotaibi, B. S. (2026) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-026-00107-w
Panda, P., Mohanty, S., & Mohapatra, R. (2026) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2026.08.003
Narasimhamurthy, R. K., N, R. K., Rajendra, V. K., & Shetty, P. (2026) · Translational research · doi:10.1016/j.trsl.2026.09.007
Gut microbiota: A key modulator of individualized efficacy and toxicity in cancer therapy
Hou, X., Chen, K., Ran, L., Pu, R., Tong, R., Li, P., Liu, K., Du, H., Liu, Y., & Hou, X. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101802
Zhong, D., Li, C., & Xiao, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1938564
Zhang, D., Hu, P., Liu, P., Tang, Y., He, H., Xu, X., & Li, X. (2026) · Acupuncture & Electro-Therapeutics Research · doi:10.1177/03601293261477462
Gut Microbiota and Microbial Metabolites in the Regulation of Chemotherapeutic Resistance
Bhowmic, S., Choudhury, P. R., Das, P., Banerjee, S., Chakrabarti, J., Juin, S. K., & Ghosh, S. (2026) · Cells · doi:10.3390/cells15211975
Metadata
- Authors
- Di Modica, M., Gargari, G., Regondi, V., Bonizzi, A., Arioli, S., Belmonte, B., De Cecco, L., Fasano, E., Bianchi, F., Bertolotti, A., Tripodo, C., Villani, L., Corsi, F., Guglielmetti, S., Balsari, A., Triulzi, T., & Tagliabue, E.
- Affiliations
- 1Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Milan (IT)
- University of Palermo (IT)
- 5Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- IFOM (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Corresponding author
- Tagliabue, Elda
- ORCID
- Venue
- Cancer Research
- Published
- 2021-01-22
- Volume
- 81
- Issue
- 8
- Pages
- 2195-2206
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3122301327
- Cited by
- 184
- References
- 54
- Citations by year
- 2026: 29 · 2025: 42 · 2024: 45 · 2023: 38 · 2022: 23 · 2021: 7
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Funders
- AIRC (IG 2017, ID. 20264)
- FIRC-AIRC fellowship (ID. 22304)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- gut microbiota, trastuzumab, HER2-positive breast cancer, antibiotic-induced dysbiosis, fecal microbiota transplantation, neoadjuvant therapy, treatment response biomarkers, dendritic cell activation, IL-12, CD4+ T cells, interferon signature, microbiome diversity, trastuzumab resistance, immunotherapy
- MeSH terms
- Trastuzumab, Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Animals, Anti-Bacterial Agents, Breast Neoplasms, Bridged-Ring Compounds, Cyclophosphamide, Dendritic Cells, Doxorubicin, Female, Humans, Immune System, Interferons, Nitric Oxide, Streptomycin, Vancomycin, CD4-Positive T-Lymphocytes, Cytokines, Treatment Outcome, Interleukin-12, Erb-b2 Receptor Tyrosine Kinases, Immunity, Mucosal, Neoadjuvant Therapy, Taxoids, Mice, Granzymes, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
